13F reference period
Q2 2026
Security Snapshot
Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR) Institutional Ownership
CUSIP: 929033207
13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026
Institutions Reporting
102
Shares (Excl. Options)
48.51M
Full value: 48,507,381 · shares · 30 Jun 2026Price
$18.41
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- VOR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 48,507,381
- Total 13F value
- $893,029,544
- Portfolio coverage rank
- 0%
- Share change
- +8,050,818
- Value change
- +$148,816,693
- Number of holders
- 102
- Shares outstanding
- 53,761,929
- SEC-reported price per share
- $19.08
- Insider filing price
- $19.08
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 929033207.
- 102 institutions reported positions in Q2 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 80 to 102 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$716.85M
Full value: $716,851,001 · USD · 31 Mar 2026.$893.03M
Full value: $893,029,544 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 102 institutions filings for Q2 2026.
Security key
929033207
13F reference period
Q2 2026
13F holders
102
13D/G owners
11
CIK / CUSIP context first
Open Q2 2026 holders
VOR full holder history
Vor Biopharma Inc. SEC filings
Vor Biopharma Inc. company facts
Vor Biopharma Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 929033207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
VOR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20% | +42% | $238,185,911 | +$138,559,809 | 12,937,855 | +139% | RA Capital Management, L.P. | 16 Jul 2026 |
| ForGrowth III PA B.V. | 10% | 0% | $81,492,203 | +$25,772,203 | 10,237,714 | +46% | ForGrowth III PA B.V. | 18 Dec 2025 |
| FMR LLC | 12% | +32% | $128,572,421 | +$31,162,478 | 6,509,996 | +32% | FMR LLC | 31 Jul 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $112,108,308 | +$11,701,737 | 5,676,370 | +12% | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2026 |
| Verve Capital Ltd | 6.3% | -33% | $67,365,117 | -$31,370,505 | 3,410,892 | -32% | Verve Capital Limited | 30 Jun 2026 |
| BlackRock, Inc. | 5.7% | $57,057,358 | 3,099,259 | BlackRock, Inc. | 30 Jun 2026 | |||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | -27% | $44,595,520 | 2,258,001 | 0% | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2026 | |
| Paradigm Biocapital Advisors LP | 4.5% | -46% | $23,730,000 | 1,750,000 | 0% | Paradigm BioCapital Advisors LP | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC | 3.3% | -39% | $18,578,651 | +$1,839,021 | 1,370,107 | +11% | Great Point Partners, LLC | 31 Dec 2025 |
| Reprogrammed Interchange LLC | 18% | $48,045,191 | 1,204,442 | Reprogrammed Interchange LLC | 15 Oct 2025 | |||
| Qiming Venture Partners VIII-HC, L.P. | 2% | -27% | $19,670,294 | 1,089,767 | 0% | Qiming Venture Partners VIII-HC, L.P. | 31 Mar 2026 |
As of 30 Jun 2026,
102
institutional investors reported holding
shares of
Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR).
This represents
90%
of the company’s total
outstanding shares.
48.51M
Full value: 48,507,381 · shares · 30 Jun 202653.76M
Full value: 53,761,929 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
83%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 11% | 5,673,078 | 0% | 2.5% | $104,441,366 |
| FMR LLC | 9.2% | 4,932,149 | +220% | 0% | $90,800,863 |
| FCPM III SERVICES B.V. | 7.7% | 4,117,354 | 0% | 10% | $75,800,487 |
| BlackRock, Inc. | 6.5% | 3,468,107 | +336% | 0% | $63,847,850 |
| Venrock Adviser, LLC | 5.7% | 3,041,719 | 0% | 1.7% | $55,998,047 |
| STATE STREET CORP | 4.9% | 2,616,336 | +134% | 0% | $48,166,746 |
| Frazier Life Sciences Management, L.P. | 4.7% | 2,543,939 | 0% | 1% | $46,833,917 |
| RA CAPITAL MANAGEMENT, L.P. | 4.5% | 2,402,095 | -56% | 0.38% | $44,222,569 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 2,084,328 | +45% | 0% | $38,372,478 |
| Caligan Partners LP | 3.6% | 1,925,066 | 0% | 1.7% | $35,440,465 |
| Paradigm Biocapital Advisors LP | 3.3% | 1,750,000 | 0% | 0.6% | $32,217,500 |
| GREAT POINT PARTNERS LLC | 3.2% | 1,700,000 | -2.9% | 7.4% | $31,297,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,062,469 | +210% | 0% | $19,563,726 |
| NEXTBio Capital Management LP | 1.7% | 889,164 | -11% | 7.5% | $16,369,509 |
| Nantahala Capital Management, LLC | 1.6% | 845,000 | 0.94% | $15,556,450 | |
| ADAR1 Capital Management, LLC | 1.3% | 680,626 | 0.59% | $12,530,325 | |
| Logos Global Management LP | 1.2% | 650,000 | -13% | 0.52% | $11,966,500 |
| Rosalind Advisors, Inc. | 1.2% | 648,600 | -7.3% | 4.5% | $11,940,726 |
| NAN FUNG TRINITY (HK) LTD | 1.2% | 646,550 | 1.2% | $11,902,986 | |
| BRAIDWELL LP | 1.1% | 573,104 | +23% | 0.39% | $10,550,845 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1% | 558,702 | +0.54% | 0.2% | $10,285,704 |
| UBS Group AG | 0.92% | 493,278 | +1% | 0% | $9,081,248 |
| MILLENNIUM MANAGEMENT LLC | 0.8% | 428,067 | +66% | 0.01% | $7,880,713 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.77% | 416,417 | +29% | 1.1% | $7,666,237 |
| Woodline Partners LP | 0.71% | 379,723 | 0.02% | $6,990,700 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Headline period
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 95,259 | $1,808,666 | -$275,591 | $19.08 | 20 |
| 2026 Q2 | 48,507,381 | $893,029,544 | +$148,816,693 | $18.41 | 102 |
| 2026 Q1 | 40,448,699 | $716,851,001 | +$247,955,353 | $17.84 | 80 |
| 2025 Q4 | 25,547,116 | $332,020,908 | +$261,622,068 | $13.08 | 54 |
| 2025 Q3 | 3,710,338 | $180,767,786 | +$180,382,226 | $48.72 | 35 |